Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Navidea Biopharmaceuticals Inc (NY: NAVB )

0.0902 -0.0028 (-3.01%)
Official Closing Price Updated: 8:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,673,538
Open 0.0900
Bid (Size) 0.0904 (1)
Ask (Size) 0.0920 (5)
Prev. Close 0.0930
Today's Range 0.0855 - 0.0927
52wk Range 0.0825 - 1.050
Shares Outstanding 35,064,475
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
Why Microvast Holdings Shares Are Trading Lower By Around 22%; Here Are 20 Stocks Moving Premarket
Gainers Applied UV, Inc. (NASDAQ: AUVI) shares rose 44.6% to $0.69 in pre-market trading after posting better-than-expected quarterly sales. 
Via Benzinga

Performance

YTD
-66.59%
-66.59%
1 Month
-60.78%
-60.78%
3 Month
-69.00%
-69.00%
6 Month
-62.23%
-62.23%
1 Year
-89.13%
-89.13%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 21, 2023
Via Benzinga
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Navidea Biopharmaceuticals Files Appeal in CRG Case
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.